Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Panés J; HIBISCUS Study Group. Rubin DT, et al. Among authors: duvall a. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):17-27. doi: 10.1016/S2468-1253(21)00338-1. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798036 Clinical Trial.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Roloff GW, Kosuri S, Nawas MT, DuVall AS, Patel AA, Riedell PA, Odenike O, Stock W, Larson RA, Bishop MR, Nunley E, Godley LA, Hathaway F, Del Gaudio D, Das S, Canham LE, Drazer MW. Roloff GW, et al. Among authors: duvall as. Haematologica. 2024 Apr 11. doi: 10.3324/haematol.2023.284584. Online ahead of print. Haematologica. 2024. PMID: 38618681 Free article.
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
Madero-Marroquin R, Dworkin E, Weiner H, Saygin C, Nawas MT, Drazer MW, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Patel AA. Madero-Marroquin R, et al. Among authors: duvall as. Leuk Lymphoma. 2024 Mar 5:1-4. doi: 10.1080/10428194.2024.2324991. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38441062 No abstract available.
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR. Badar T, et al. Among authors: duvall as. Blood Cancer J. 2024 Feb 20;14(1):32. doi: 10.1038/s41408-024-01000-2. Blood Cancer J. 2024. PMID: 38378617 Free PMC article.
Raptor Pediatrics.
Duvall A. Duvall A. Vet Clin North Am Exot Anim Pract. 2024 May;27(2):359-378. doi: 10.1016/j.cvex.2023.11.012. Epub 2023 Dec 18. Vet Clin North Am Exot Anim Pract. 2024. PMID: 38110317 Review.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Johnston H, Youshanlouei HR, Osei C, Patel AA, DuVall A, Wang P, Wanjari P, Segal J, Venkataraman G, Cheng JX, Gurbuxani S, Lager A, Fitzpatrick C, Thirman M, Nawas M, Liu H, Drazer M, Odenike O, Larson R, Stock W, Saygin C. Johnston H, et al. Among authors: duvall a. Blood Adv. 2024 Jan 9;8(1):164-171. doi: 10.1182/bloodadvances.2023011862. Blood Adv. 2024. PMID: 38039510 Free PMC article.
144 results